3 reports

  • Dec 01, 2017: AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases
  • Apr 05, 2018: AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer's disease

Iqbal commented: " Neurodegeneration leads to Tau pathology and Tau pathology leads to neurodegeneration.

  • Pathology
  • United States
  • World
  • Company Financials
  • AC Immune SA
  • 11/21/2017: AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimers and other Neurodegenerative Diseases
  • Aug 22, 2017: AC Immune Discovers Next-generation Antibodies Focused On Neurodegenerative Diseases

The support of MJFF further validates AC Immune' s leading expertise in the pathology of misfolded proteins.

  • Dementia
  • Pathology
  • Pharmaceutical
  • United States
  • AC Immune SA
  • May 02, 2018: AC Immune Reports First Quarter 2018 Financial Results and Corporate Update
  • Mar 20, 2018: AC Immune reports full-year 2017 financial results - successful first year as a public company

He also addressed inhibition and prevention of Tau pathology, which may potentially disrupt the progression of Alzheimer' s disease and improve cognitive impairment.

  • Dementia
  • Pathology
  • United States
  • Company Operations
  • AC Immune SA